Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.

Enzalutamide is an androgen receptor (AR) inhibitor approved for therapy of metastatic castration resistant prostate cancer. However, clinical application revealed that 30 to 40% of patients acquire resistance after a short period of treatment. Currently, the molecular mechanisms underlying such resistances are not completely understood, partly due to a lack of model systems. In the present study we established three different cellular models of enzalutamide resistance including a cell line with wild type AR (LAPC4), DuCaP cells which overexpress wild-type AR, as well as a cell which has been adapted to long term androgen ablation (LNCaP Abl) and harbors the AR T878A mutation. After 10 months of cultivation, sustained growth in the presence of enzalutamide was achieved. When compared to controls, resistant cells exhibit significantly decreased sensitivity to enzalutamide as measured with 3[H]thymidine incorporation and WST assay. Moreover, these cell models exhibit partly re-activated AR signaling despite presence of enzalutamide. In addition, we show that enzalutamide resistant cells are insensitive to bicalutamide but retain considerable sensitivity to abiraterone. Mechanistically, enzalutamide resistance was accompanied by increased AR and AR-V7 mRNA and protein expression as well as AR gene amplification, while no additional AR mutations have been identified.

Oncotarget. 2016 Jul 29 [Epub ahead of print]

Julia Hoefer, Mohammady Akbor, Florian Handle, Philipp Ofer, Martin Puhr, Walther Parson, Zoran Culig, Helmut Klocker, Isabel Heidegger

Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria., Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria., Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria., Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria., Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria., Institute of Legal Medicine, Medical University of Innsbruck, Austria., Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria., Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria., Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Austria.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe